PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 6, 2026Proceedings of the National Academy of Sciences0 citations

NMI promotes the secretion of IL-17 and exacerbates psoriasis

View Full Paper
YGYaqi GaoYWYì WángZQZhen Qin

Key Points

  • To investigate the role of NMI in regulating Th17 cell activity and its implications in psoriasis.
  • Characterization of NMI in psoriatic skin samples
  • Murine model experiments assessing Nmi deficiency
  • In vitro assays measuring IL-17A and IL-17F secretion
  • Therapeutic neutralization of NMI with specific antibodies
  • Elevated NMI levels were found in psoriatic lesions, correlating with increased IL-17 levels.
  • Nmi deficiency in mice led to reduced skin inflammation and lower IL-17A and IL-17F expression.
  • NMI promoted IL-17A and IL-17F secretion from Th17 cells via Toll-like receptor 4 interactions.
  • Neutralizing antibodies against NMI reduced psoriatic symptoms in murine models.

Abstract

Damage-associated molecular patterns (DAMPs) are well established as key mediators of innate immune activation; however, their functions in modulating adaptive immunity, particularly T cell responses, remain incompletely characterized. Here, we report the identification and functional characterization of NMI—a recently identified DAMP—as a regulator of T helper 17 (Th17) cell activity and its involvement in psoriasis pathogenesis. Elevated expression of NMI was observed in psoriatic skin lesions and correlated significantly with heightened IL-17 levels. In a murine model of psoriasis, Nmi deficiency ( Nmi −/− ) resulted in a marked attenuation of skin inflammation, accompanied by significantly reduced expression of IL-17A and IL-17F. In vitro studies further demonstrated that NMI promotes the secretion of IL-17A and IL-17F from differentiated Th17 cells through its interaction with Toll-like receptor 4. Moreover, therapeutic neutralization of NMI using specific antibodies effectively ameliorated psoriatic symptoms in mice. Collectively, these results identify NMI as an endogenous enhancer of Th17-mediated immunity and highlight its potential as a therapeutic target in psoriasis.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gao et al. (2026) studied this question.

synapsesocial.com/papers/69aa705a531e4c4a9ff5a011https://doi.org/10.1073/pnas.2511535123
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1TLR4-RelA-miR-30a signal pathway regulates Th17 differentiation during experimental autoimmune encephalomyelitis development2019 · 28 citations
  2. 2IL-23 drives a pathogenic T cell population that induces autoimmune inflammation2005 · 4,089 citations
  3. 3Increased level of high mobility group box 1 in the serum and skin in patients with generalized pustular psoriasis2020 · 17 citations
  4. 4Pathogenesis and clinical features of psoriasis2007 · 2,153 citations
  5. 5Does HSP90 play an important role in psoriasis?2021 · 8 citations